Value through Innovation27 July 2016

Clinical Study Results

  • VARGATEF ® - Ovarian Neoplasms
    Clinical Study Number 1199.15
    Study Indication Ovarian Neoplasms
    Product VARGATEF ®
    Generic Name Nintedanib
    Lab Code
    Clinical Phase IIIa
    Study Title

    Multicenter, randomised, double-blind Phase III trial to investigate the efficacy and safety of BIBF 1120 in combination with carboplatin and paclitaxel compared to placebo plus carboplatin and paclitaxel in patients with advanced ovarian cancer

    Study Document Trial synopsis 1199.15 english Lay summary 1199.15 english
  • VARGATEF ® - Ovarian Neoplasms
    Clinical Study Number 1199.9
    Study Indication Ovarian Neoplasms
    Product VARGATEF ®
    Generic Name Nintedanib
    Lab Code
    Clinical Phase II
    Study Title

    A randomised placebo-controlled phase II study of continuous maintenance treatment with BIBF 1120 following chemotherapy in patients with relapsed ovarian cancer

    Study Document Trial synopsis 1199.9_DS_DR english
  • VARGATEF ® - Ovarian Neoplasms
    Clinical Study Number 1199.117
    Study Indication Ovarian Neoplasms
    Product VARGATEF ®
    Generic Name Nintedanib
    Lab Code
    Clinical Phase I
    Study Title

    An open label, dose escalation phase I study of the safety and tolerability of BIBF 1120 in combination with carboplatin and pegylated liposomaldoxorubicin (PLD) in Japanese patients with a first, second or third platinum sensitive relapse of advanced epithelial ovarian cancer (OC), fallopian tube or primary peritoneal cancer 

    Study Document Trial synopsis 1199.117_DR english
  • VARGATEF ® - Ovarian Neoplasms
    Clinical Study Number 1199.119
    Study Indication Ovarian Neoplasms
    Product VARGATEF ®
    Generic Name Nintedanib
    Lab Code
    Clinical Phase I
    Study Title

    Phase I dose escalation trial to determine the maximum tolerated dose of BIBF 1120 in combination with carboplatin and pegylated liposomal doxorubicin (PLD) in patients with a first, second or third platinum sensitive relapse of advanced epithelial ovarian cancer, fallopian tube or primary peritoneal cancer

    Study Document Trial synopsis 1199.119_primary_anal english Trial synopsis 1199.119_final english Lay summary 1199.119 english
  • Volasertib - Ovarian Neoplasms
    Clinical Study Number 1230.18
    Study Indication Ovarian Neoplasms
    Product Volasertib
    Generic Name Volasertib
    Lab Code BI 6727
    Clinical Phase II
    Study Title

    Phase II randomized trial of the Polo-like kinase 1 inhibitor BI 6727 monotherapy versus investigator’s choice chemotherapy in ovarian cancer patients resistant or refractory to platinum-based cytotoxic therapy

    Study Document Trial synopsis 1230.18_DR english

Clinical Trial Registry and structured study results. Find here protocol information for all clinical study types.

European Trial Register of EU studies.